Table 5 Multivariable Cox regression model for the development of anemia.

From: Circulating Fibroblast Growth Factor-23 Levels are Associated with an Increased Risk of Anemia Development in Patients with Nondialysis Chronic Kidney Disease

 

Model 1a

Model 2b

Model 3c

Model 4d

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

FGF23 quartile

Quartile 1

Reference

Reference

Reference

Reference

Quartile 2

1.65 (1.13–2.40)

0.009

1.48 (1.02–2.16)

0.04

1.23 (0.81–1.87)

0.34

1.22 (0.80–1.85)

0.36

Quartile 3

2.55 (1.80–3.62)

<0.001

2.15 (1.51–3.07)

<0.001

1.71 (1.15–2.54)

0.008

1.66 (1.11–2.47)

0.01

Quartile 4

2.94 (2.07–4.17)

<0.001

2.42 (1.70–3.45)

<0.001

1.95 (1.31–2.90)

0.001

1.84 (1.23–2.76)

0.003

FGF23 (per 1 log)

1.32 (1.22–1.43)

<0.001

1.26 (1.16–1.36)

<0.001

1.19 (1.08–1.31)

<0.001

1.17 (1.07–1.29)

0.001

  1. Note: FGF23 entered as a categorical and continuous form (log transformed).
  2. aUnadjusted model.
  3. bAdjusted for age, sex, DM, BMI, SBP, CCI, smoking status.
  4. cAdjusted for Model 2 + eGFR, albumin, phosphorus, 1,25(OH)2 vitamin D, iron deficiency, hepcidin*, CRP*, and proteinuria*.
  5. dAdjusted for Model 3 + iron replacement and ESA therapy.
  6. *Variables were log transformed.
  7. Abbreviations: FGF23, fibroblast growth factor 23; DM, diabetes mellitus; BMI, body mass index; SBP, systolic blood pressure; CCI, Charlson comorbidity index; eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; ESA, erythropoiesis-stimulating agent.
Back to article page